ReviewHepatology international2025
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease.
Harendran Elangovan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it